PRESS RELEASE published on 11/11/2025 at 07:24, 7 months 15 days ago Medios AG achieves strong growth in earnings and profit margin in the first nine months of 2025 Medios AG achieves 9.2% revenue growth and 26.1% increase in EBITDA pre1 in the first nine months of 2025. New CEO appointed. Outlook confirmed. Details in press release EBITDA Revenue Growth CEO Appointment Medios AG 2025 Outlook
BRIEF published on 11/03/2025 at 10:02, 7 months 23 days ago Thomas Meier nommé PDG de Medios AG Stratégie De Croissance Medios AG Nomination Du PDG Pharmacie Spécialisée Thomas Meier
BRIEF published on 11/03/2025 at 10:02, 7 months 23 days ago Thomas Meier Appointed CEO of Medios AG Growth Strategy CEO Appointment Medios AG Specialty Pharma Thomas Meier
PRESS RELEASE published on 11/03/2025 at 09:57, 7 months 23 days ago Thomas Meier becomes new CEO of Medios AG Thomas Meier appointed as new CEO of Medios AG effective February 1, 2026, succeeding Matthias Gaertner. Meier's past roles include CEO of Bachem Holding AG. Medios AG aims for further growth under his leadership CEO Appointment Medios AG Specialty Pharma Thomas Meier Bachem Holding AG
BRIEF published on 10/24/2025 at 11:09, 8 months 2 days ago Medios AG : Réattribution des actions Bencis Medios AG Pharmaceutique Spécialisée Réallocation Des Actions Bencis Capital Partners Groupe Janus Henderson
BRIEF published on 10/24/2025 at 11:09, 8 months 2 days ago Medios AG: Reallocation of Bencis Shares Medios AG Specialty Pharma Share Reallocation Bencis Capital Partners Janus Henderson Group
PRESS RELEASE published on 10/24/2025 at 11:04, 8 months 2 days ago Medios AG: Reallocation of Bencis shares Medios AG announces reallocation of Bencis shares to Janus Henderson, representing approximately 6.7% of share capital. Bencis sold shares acquired in 2024 through capital increase related to Ceban Pharmaceuticals B.V Janus Henderson Medios AG Specialty Pharma Bencis Shares Individualized Medicine
BRIEF published on 08/13/2025 at 07:42, 10 months 13 days ago Medios AG annonce une forte croissance au premier semestre 2025 Medios AG Croissance Des Revenus Augmentation De L'EBITDA S1 2025 Segments Pharmaceutiques
BRIEF published on 08/13/2025 at 07:42, 10 months 13 days ago Medios AG Reports Strong Growth in H1 2025 Revenue Growth Medios AG EBITDA Increase H1 2025 Pharmaceutical Segments
PRESS RELEASE published on 08/13/2025 at 07:37, 10 months 13 days ago Medios accelerates growth in the first half of 2025 and significantly increases earnings Medios accelerates growth in the first half of 2025, with revenue up by 9.3% to €991.7 million and EBITDA significantly increasing by 48.8%. Successful share buyback. Positive outlook for 2025 EBITDA Revenue Outlook Growth Medios
Published on 06/26/2026 at 01:40, 10 hours 8 minutes ago UraniumX Announces DTC Eligibility for U.S. Traded Shares
Published on 06/25/2026 at 23:30, 12 hours 18 minutes ago Zeus North America Mining Corp. Signs Option Agreement to Acquire Mining Claims in Idaho
Published on 06/25/2026 at 22:30, 13 hours 18 minutes ago Fountain Asset Corp. Provides Corporate Update
Published on 06/25/2026 at 21:32, 14 hours 16 minutes ago BlackBerry Announces Election Results for the Company's Board of Directors
Published on 06/25/2026 at 15:30, 20 hours 18 minutes ago Silver Spruce Resources, Inc. Adds Mining, Energy, and Finance Development Expertise to the Board and Announces Director Resignation
Published on 06/26/2026 at 11:14, 33 minutes ago EQS-Adhoc: Evonik Industries AG: Current financial and forecast data for the second quarter of 2026 and adjustment of the outlook for the financial year 2026
Published on 06/26/2026 at 11:05, 42 minutes ago Join the Beautiful Game: Discover Immersive Fan Experiences with Hisense at FIFA World Cup 2026™
Published on 06/26/2026 at 10:59, 48 minutes ago HELIOS SOLAR AG starts subscription period for Initial Public Offering – shares offered at EUR 4.00
Published on 06/26/2026 at 10:50, 57 minutes ago Indotek Group acquires remaining 53% stake in Auchan Hungary, assumes full ownership
Published on 06/26/2026 at 07:00, 4 hours 48 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 4 hours 48 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/25/2026 at 18:45, 17 hours 2 minutes ago Avis Financier Semestriel SFCMC au 30 avril 2026
Published on 06/25/2026 at 18:30, 17 hours 18 minutes ago Avis financier semestriel SIEHM au 30 avril 2026
Published on 06/25/2026 at 17:50, 17 hours 58 minutes ago DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
